AstraZeneca’s COVID-19 vaccine is 74 percent effective in preventing symptomatic illness, according to data from its U.S. clinical trial published in the New England Journal of Medicine on Wednesday.
The phase 3 trial involved more than 32,000 participants in the United States, Peru, and Chile, who either received two doses of the COVID-19 vaccine or a saline injection four weeks apart. However, data was based only on 26,212 participants.
